Company news
Indaptus Therapeutics, Inc. news in 2022
Indaptus Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors
December 12, 2022
Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 9, 2022
Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 7, 2022
Indaptus Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Decoy20 in Solid Tumors
May 18, 2022
Indaptus Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 11, 2022
Indaptus Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results and Provides Corporate Update
March 20, 2022
Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer
January 2, 2022